Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 92

1.

Macrophage infiltration and genetic landscape of undifferentiated uterine sarcomas.

Przybyl J, Kowalewska M, Quattrone A, Dewaele B, Vanspauwen V, Varma S, Vennam S, Newman AM, Swierniak M, Bakuła-Zalewska E, Siedlecki JA, Bidzinski M, Cools J, van de Rijn M, Debiec-Rychter M.

JCI Insight. 2017 Jun 2;2(11). pii: 94033. doi: 10.1172/jci.insight.94033. [Epub ahead of print]

2.

MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation.

Schaefer IM, Wang Y, Liang CW, Bahri N, Quattrone A, Doyle L, Mariño-Enríquez A, Lauria A, Zhu M, Debiec-Rychter M, Grunewald S, Hechtman JF, Dufresne A, Antonescu CR, Beadling C, Sicinska ET, van de Rijn M, Demetri GD, Ladanyi M, Corless CL, Heinrich MC, Raut CP, Bauer S, Fletcher JA.

Nat Commun. 2017 Mar 8;8:14674. doi: 10.1038/ncomms14674.

3.

Mapping a multiplexed zoo of mRNA expression.

Choi HM, Calvert CR, Husain N, Huss D, Barsi JC, Deverman BE, Hunter RC, Kato M, Lee SM, Abelin AC, Rosenthal AZ, Akbari OS, Li Y, Hay BA, Sternberg PW, Patterson PH, Davidson EH, Mazmanian SK, Prober DA, van de Rijn M, Leadbetter JR, Newman DK, Readhead C, Bronner ME, Wold B, Lansford R, Sauka-Spengler T, Fraser SE, Pierce NA.

Development. 2016 Oct 1;143(19):3632-3637.

4.

CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.

Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer JP, Liu J, Lim JS, Yang D, Seitz G, Nguyen T, Wu D, Jude K, Guerston H, Barkal A, Trapani F, George J, Poirier JT, Gardner EE, Miles LA, de Stanchina E, Lofgren SM, Vogel H, Winslow MM, Dive C, Thomas RK, Rudin CM, van de Rijn M, Majeti R, Garcia KC, Weissman IL, Sage J.

J Clin Invest. 2016 Jul 1;126(7):2610-20. doi: 10.1172/JCI81603. Epub 2016 Jun 13.

5.

Giant Pulmonary Artery Aneurysm in a Patient With Marfan Syndrome and Pulmonary Hypertension.

Chiu P, Irons M, van de Rijn M, Liang DH, Miller DC.

Circulation. 2016 Mar 22;133(12):1218-21. doi: 10.1161/CIRCULATIONAHA.115.020537. No abstract available.

6.

Loss of H3K27 tri-methylation is a diagnostic marker for malignant peripheral nerve sheath tumors and an indicator for an inferior survival.

Cleven AH, Sannaa GA, Briaire-de Bruijn I, Ingram DR, van de Rijn M, Rubin BP, de Vries MW, Watson KL, Torres KE, Wang WL, van Duinen SG, Hogendoorn PC, Lazar AJ, Bovée JV.

Mod Pathol. 2016 Jun;29(6):582-90. doi: 10.1038/modpathol.2016.45. Epub 2016 Mar 18.

7.

CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.

Dalerba P, Sahoo D, Paik S, Guo X, Yothers G, Song N, Wilcox-Fogel N, Forgó E, Rajendran PS, Miranda SP, Hisamori S, Hutchison J, Kalisky T, Qian D, Wolmark N, Fisher GA, van de Rijn M, Clarke MF.

N Engl J Med. 2016 Jan 21;374(3):211-22. doi: 10.1056/NEJMoa1506597.

8.

Extraskeletal osteosarcoma of the hand: the role of marginal excision and adjuvant radiation therapy.

Casey DL, van de Rijn M, Riley G, Tung KW, Mohler DG, Donaldson SS.

Hand (N Y). 2015 Dec;10(4):602-6. doi: 10.1007/s11552-015-9760-0. Epub 2015 Apr 17. Review.

9.

Molecular subtyping of leiomyosarcoma with 3' end RNA sequencing.

Guo X, Forgó E, van de Rijn M.

Genom Data. 2015 Sep 1;5:366-367.

10.

KIT Signaling Promotes Growth of Colon Xenograft Tumors in Mice and Is Up-Regulated in a Subset of Human Colon Cancers.

Chen EC, Karl TA, Kalisky T, Gupta SK, O'Brien CA, Longacre TA, van de Rijn M, Quake SR, Clarke MF, Rothenberg ME.

Gastroenterology. 2015 Sep;149(3):705-17.e2. doi: 10.1053/j.gastro.2015.05.042. Epub 2015 May 28.

11.

Clinically Relevant Molecular Subtypes in Leiomyosarcoma.

Guo X, Jo VY, Mills AM, Zhu SX, Lee CH, Espinosa I, Nucci MR, Varma S, Forgó E, Hastie T, Anderson S, Ganjoo K, Beck AH, West RB, Fletcher CD, van de Rijn M.

Clin Cancer Res. 2015 Aug 1;21(15):3501-11. doi: 10.1158/1078-0432.CCR-14-3141. Epub 2015 Apr 20.

12.

A role for versican in the development of leiomyosarcoma.

Keire PA, Bressler SL, Lemire JM, Edris B, Rubin BP, Rahmani M, McManus BM, van de Rijn M, Wight TN.

J Biol Chem. 2014 Dec 5;289(49):34089-103. doi: 10.1074/jbc.M114.607168. Epub 2014 Oct 15.

13.

Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil.

Carvalho FM, Bacchi LM, Pincerato KM, Van de Rijn M, Bacchi CE.

BMC Womens Health. 2014 Aug 29;14:102. doi: 10.1186/1472-6874-14-102.

14.

Progressive loss of myogenic differentiation in leiomyosarcoma has prognostic value.

Demicco EG, Boland GM, Brewer Savannah KJ, Lusby K, Young ED, Ingram D, Watson KL, Bailey M, Guo X, Hornick JL, van de Rijn M, Wang WL, Torres KE, Lev D, Lazar AJ.

Histopathology. 2015 Apr;66(5):627-38. doi: 10.1111/his.12466. Epub 2015 Jan 12.

15.

Dystrophin is a tumor suppressor in human cancers with myogenic programs.

Wang Y, Marino-Enriquez A, Bennett RR, Zhu M, Shen Y, Eilers G, Lee JC, Henze J, Fletcher BS, Gu Z, Fox EA, Antonescu CR, Fletcher CD, Guo X, Raut CP, Demetri GD, van de Rijn M, Ordog T, Kunkel LM, Fletcher JA.

Nat Genet. 2014 Jun;46(6):601-6. doi: 10.1038/ng.2974. Epub 2014 May 4.

16.

Stromal responses among carcinomas--response.

West RB, van de Rijn M, Chen JL.

Clin Cancer Res. 2014 Mar 1;20(5):1397. doi: 10.1158/1078-0432.CCR-13-3238. No abstract available.

17.

Next generation sequencing-based expression profiling identifies signatures from benign stromal proliferations that define stromal components of breast cancer.

Guo X, Zhu SX, Brunner AL, van de Rijn M, West RB.

Breast Cancer Res. 2013 Dec 17;15(6):R117. doi: 10.1186/bcr3586.

18.

Molecular pathological analysis of sarcomas using paraffin-embedded tissue: current limitations and future possibilities.

van de Rijn M, Guo X, Sweeney RT, Beck AH, West RB.

Histopathology. 2014 Jan;64(1):163-70. doi: 10.1111/his.12290. Epub 2013 Nov 25. Review.

19.

Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors.

Edris B, Willingham S, Weiskopf K, Volkmer AK, Volkmer JP, Mühlenberg T, Weissman IL, van de Rijn M.

Oncoimmunology. 2013 Jun 1;2(6):e24452. Epub 2013 May 14.

20.

Stromal responses among common carcinomas correlated with clinicopathologic features.

Chen JL, Espinosa I, Lin AY, Liao OY, van de Rijn M, West RB.

Clin Cancer Res. 2013 Sep 15;19(18):5127-35. doi: 10.1158/1078-0432.CCR-12-3127. Epub 2013 Jun 26.

Supplemental Content

Loading ...
Support Center